ORA Orange long assuming low is behind usNot sure about the irregular flat pattern (correction of the high @10,865) but assuming the last movement was a C wave and assuming this C wave can be divided in an 5 waves impulse then the low would be behind us @9,159. A little frustating is the fact that the gap @9,156 has not been filled
Anyway in this case a entry point would be the breakout of the 4th wave = 9,676
stop easy under the last lows @9,159
short term target around 10 but here the trade idea is more to get in for the long term, so targeting values above the 10,865, for instance the 1,618 fibo level @ 12,245
@ASML not a bad chance to buylooking forward to buy this chart
probably it will be a dollar-cost averaging with some leverage
French market - Edenred company - 4 wavesTriangle (III. - IV) out, and re test now.
Go to 5 wave. Finish 55-60 euro.
CGG return to 0.80 ?Due to increas of oil CGG is carried on a positive trend and next resistance is at 80
$TTE #total #short and pt 39E- #fp $fp the psi is too high
the volume every day is decreasing
and
tte don't make new highs ....
absolutely SHORT
fibo at 39 is 0,618
Fastned: Expecting lower- lot of untouched prices below current pricefloor ('air').
-continued downtrend.
- support is multiple times tapped and reaction from it becomes weaker.
$tte $fp #total short under 39euro #stock #oil huge rise for the oil and for the oil stocks .
now is the time to buy the sell options 39 euro for this stock
the rsi is too overvalued and fund the previous resistance
we had profit taking today and tomorow as the oil price has already started to decline would be more intense .
disclaimer
CARMAT SAS EURONEXT LONGCarmat SAS is a France-based Company engaged in the development and production of heart prosthesis.
enter price:25.8; stop-loss 23.30; target price 33.60.
Carmat's RSI looks strong and shows upwards momentum, therefore a drastic trend reversal or corrective pullback are unlikely to occur in the near future.
DMI the indicator in these situation can't be easily interpreted but we can identify a little bullish trend that is ready to growth.
MACD suggest that the graph is in a good bull trend.
The news told that Carmat has lunch its product in the U.S in 23 september. this fact can uphold our analysis.
NO FINANCIAL ADVISE
Range break out. Up trendRSI divergence from March.
Down trend canal hit after triangle break.
Ichimoku indicator show us an up trend to, over TS and KS and until yesterday LS is free.
Target on white rectangles
Dieteren possible retracement (sold all my positions)Possible retracement Idea for Dieteren and the temporarely top after a good way up.
Possible 10% drop on Kinepolis group (short trade)After looking at the FIB retracement levels this is the ideal RR to open a short position on Kinepolis group. TP would be 50.55, SL would be 58 wich makes it a 2,3 RR
ALFEN Daily TimeframeSNIPER STRATEGY
This magical strategy works like a clock on almost any charts
Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading.
It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave.
The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes.
Start believing in this strategy because it will reward believers with huge profit.
There is a lot more about this strategy.
It can predict and also it can give you almost exact buy or sell time on the spot.
I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
BN Danonethe next month for Danone will be going to have a bear tendance and the price will be down at 43.5 so i recommand to sell bn for the next month
BIO-UV - long 6.67%Pullback before bull
TS looking up
KS upper trend
LS rejected on resistance, a chance to buy the dips before next
Final target on 0.38 fibo
LVMH (MC.PA)LVMH is a vastly diversified company with 75+ brands from fashion, jewelry, leather, cosmetics, perfumes, stores, alcohol, media and financial services. LVMH has a few of the most desirable luxury brands in the world in its portfolio. Inflation isn't a problem at all, but more a possible catalyst for the company: high-end luxury items are investments and collectables. LVMH had a good start in 2021: all business segments contributed to organic revenue growth.
Please take a look here:
r.lvmh-static.com
LVMH overvaluation is not the specfic problem for LVMH, but for the entire stock market. The inflation is not the problem: luxury brands can increase the price. You should buy companies which can increase the price easily when the inflation is coming. LVMH is overvalued right now (5% -15%). It's not the right time to invest in this great company. Entry point could be around 570€.
Own it, don’t trade it.
MCPHY cassure de range (ratio: 3.15)On a cassé le range par le haut hier, on observe aujourd'hui un pullback qui vient retester notre rectangle suite au rejet de la chiku par la Kijun, s'il on clotûre au dessus du rectangle ( et que la chiku nous confirme) on aura un fort signal haussier, avec une target clairement définie.
Insurance and Airline Companies / HurricaneThe storm is also likely to hit insurers and airlines hard
TKWY possible scenarios. Bullish expectationsTwo possible outcomes when looked at the near future. Bullish outlook based on the growth and being undervalued.
ALFEN - LongThis could be the 3rd way undergoing. I hope that it won't be a double top pattern..
First target could be at 100% of the first wave.
Trendchannel TKWYTKWY is in a downtrend at the moment. Set an alert at €82. If it breaks out of the channel it will probably move up. Large shareholders like Cat Rock Capital have been complaining about the shareprice of TKWY. They think shares of TKWY have a big discount compaired to their rivals.
Also: BoA and Goldman both have a price target of €130-135 on TKWY.
Will TKWY shake of the worries among shareholders about the takeover of GrubHub?
Note: no financial advise! Just my opinion.
ATOS ATO long entry for swing tradeAssuming a correction of the last movement to the 38,2% fibo level around 41,2
Level confirmed by the c target of the abc ongoing correction
stop easy under the last lows around 38,5
targets:
either we are in a impulse wave --> target at least 161,8% fibo at 49 (orange scenario)
or we are in ABC correction (red scenario) --> target when AB=BC, around 47
on the middle term we may be in a 4th wave of a bearish movement, therefore this trade is only for short term
A lower low could come on the long term to complete the pattern
see also .tradingview.com/chart/ATO/iLDRPY31-ATOS-looking-for-entry-point/
ALNOV Novacyt Graham Mullis, Group CEO of Novacyt, commented:
“Novacyt is continuing to address COVID-19 testing for both current and future demand. We continue to ensure that innovation is at the centre of our strategy and that our growing portfolio of COVID-19 tests are available to customers in both private and public health settings to expand existing, and support new, partnerships. Throughout the pandemic, NHS testing demand has remained a key priority for the Company and the contract award under the PHE National Microbiology Framework is a testament to our continued commitment.
“We believe our long-term strategy also supports the growth of Novacyt post-COVID-19. In particular, our progress and growth potential in the private sector will not only help us maximize the COVID-19 testing opportunity but also ensure we are well placed, with both technologies and partners, for sustainable growth beyond COVID-19. We therefore believe Novacyt is well positioned to continue to build on its business transformation.”
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
